Flourish Research

Adult ADHD Self-Scheduler


To qualify for this study, participants must:

  • Be 18 to 55 years old
  • BMI less than 18.5 or greater than 40 kg/m2 at screening [to calculate:Click here]
  •  Be diagnosed with ADHD for at least 6 months
  • Not have treatment-resistant ADHD based on a history of receipt of more than 2 approved ADHD medications that failed to improve symptoms
  • Not have a history of taking solriamfetol/Sunosi
  • Not have a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin in the past 5 years
  •  Not have attempted suicide in the last 2 years
  •  Not have a history of drug dependence or substance disorder within the last 12 months
  • Not have a history of or currently be taking:
    • phenytoin
    • carbamazepine
    • lamotrigine
    • valproic acid
    • an antipsychotic medication
    • or lithium (any lithium preparation or formulation)
  • Not have a known renal insufficiency or significant renal impairment
  • Not have donated or had blood loss of more than 450 mL in the last 30 days
  • Not have severe drug allergy or hypersensitivity
  • Not have significant cardiovascular disease
  • Not have hepatitis B, hepatitis C, or HIV (human immunodeficiency virus)
  • If you are a woman of childbearing potential or a man whose partner is of childbearing potential, you must agree to use effective birth control
  • Additional criteria will apply

PLEASE NOTE: Please confirm your eligibility before your appointment by calling 210-949-0122

If you do not see an available appointment, please call 210-949-0122 for availability.

Transportation may be available. Call 210-949-0122. Compensation up to $575 is available for time and travel.

By signing up you agree to receive text messages and emails about this and similar studies near you. You can unsubscribe at any time. Text messages and data rates may apply.

Schedule Appointment
Flourish Research News

Stay current with the latest clinical trial news and learn how Flourish Research is supporting the advancement of life-changing therapeutics.